產(chǎn)品詳情
簡單介紹：
Anti-PLEKHA7抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購！我公司長期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-PLEKHA7抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-PLEKHA7
Cat. Number:
Anti-PLEKHA7抗體KL-13730R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
PLEKHA7 (pleckstrin homology domain containing, family A member 7), also known as PH domain-containing family A member 7, is a 1,121 amino acid protein that contains one PH domain and two WW domains. Encoded by a Anti-PLEKHA7抗體gene that maps to human chromosome 11p15.1, PLEKHA7 exists as three alternatively spliced isoforms. Localizing to cell-cell junctions in Caco2 cells, PLEKHA7 interacts with the adherens junction protein p120 in human colon carcinoma cells. PLEKHA7 also colocalizes with zona adherens proteins and is necessary for zonula adherens biogenesis and maintenance. Associated with systolic blood pressure (SBP) and hypertension, PLEKHA7 is a potential target for the prevention or treatment of hypertension. PLEKHA7 is also linked to autoimmune hepatitis type 1, a chronic active hepatitis characterized by hypergammaglobulinemia and autoantibodies.
Also known as:
DKFZp686M22243; PHAnti-PLEKHA7抗體 domain-containing family A member 7; PKHA7_HUMAN; Pleckstrin homology domain containing family A member 2; Pleckstrin homology domain-containing family A member 7; Plekha7.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, .
●
Immunogen: KLH conjugated Anti-PLEKHA7抗體synthetic peptide derived from human PLEKHA7.
●
Predicted Molecular Weight: 127kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 Anti-PLEKHA7抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
